NASDAQ:RYTM - Rhythm Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $28.44 +0.94 (+3.42 %) (As of 11/14/2018 08:48 AM ET)Previous Close$27.50Today's Range$27.50 - $29.6852-Week Range$16.80 - $37.23Volume121,664 shsAverage Volume124,550 shsMarket Capitalization$939.82 millionP/E Ratio-10.05Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Rhythm Pharmaceuticals, Inc. is a subsidiary of Motus Therapeutics, Inc. Receive RYTM News and Ratings via Email Sign-up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RYTM Previous Symbol CUSIPN/A Webwww.rhythmtx.com Phone857-264-4280 Debt Debt-to-Equity RatioN/A Current Ratio35.45 Quick Ratio40.16 Price-To-Earnings Trailing P/E Ratio-10.05 Forward P/E Ratio-14.66 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$7.89 per share Price / Book3.60 Profitability EPS (Most Recent Fiscal Year)($2.83) Net Income$-33,700,000.00 Net MarginsN/A Return on Equity-28.44% Return on Assets-27.50% Miscellaneous Employees26 Outstanding Shares34,170,000Market Cap$939.82 million OptionableOptionable Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions What is Rhythm Pharmaceuticals' stock symbol? Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM." How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) issued its quarterly earnings data on Friday, November, 9th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.06. View Rhythm Pharmaceuticals' Earnings History. When is Rhythm Pharmaceuticals' next earnings date? Rhythm Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Rhythm Pharmaceuticals. What price target have analysts set for RYTM? 4 brokers have issued 1-year price objectives for Rhythm Pharmaceuticals' stock. Their forecasts range from $36.00 to $42.00. On average, they expect Rhythm Pharmaceuticals' stock price to reach $39.00 in the next year. This suggests a possible upside of 37.1% from the stock's current price. View Analyst Price Targets for Rhythm Pharmaceuticals. What is the consensus analysts' recommendation for Rhythm Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rhythm Pharmaceuticals. What are Wall Street analysts saying about Rhythm Pharmaceuticals stock? Here are some recent quotes from research analysts about Rhythm Pharmaceuticals stock: 1. Stifel Nicolaus analysts commented, "We update our model accordingly. Overall, our thesis remains unchanged and while we continue to model a high POS for setmelanotide as a treatment for rare genetic obesity disorders, we feel this is largely factored into the stock, and ultimately the lack of near-term catalysts and questions around the size of the commercial opportunity for POMC and LepR deficiency obesities keeps us on the sidelines for now. The company continues to make good progress in its setmelanotide Phase 3 programs and we think any incremental updates on the status of its TEMPO registry efforts to identify patients with genetic obesities, particularly ones which could be treated with setmelanotide, could prove to be positive catalysts if it looks like the prevalence of these disorders are greater than clinical epidemiology/literature has shown. We maintain our Hold rating and $36 target price." (11/11/2018) 2. According to Zacks Investment Research, "Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA. " (8/15/2018) 3. Needham & Company LLC analysts commented, "We hosted a series of mtgs with mgmt and investors last wk. Enrollment in setmelanotide Phase 3 trial in POMC patients is nearing completion. Mgmt did not disclose current enrollment figure, but did reiterate guidance for completion in 1H18. Phase 3 trial in LepR patients has been initiated. Mgmt still expects to complete enrollment of this latter trial by YE18, noting help from an overlap in sites w/ POMC trial and higher prevalence. A mtg w/ FDA to discuss Bardet-Biedl Phase 3 design is scheduled. Trial likely to be somewhat larger, but it is not yet clear whether a placebo arm will be needed. We expect initial data from Phase 2 testing in Alstrom, Epigenetic POMC, and possibly Heterozygous POMC patients in 1H18. Mgmt did not guide on timing for an update on Bardet-Biedl Phase 2 trial, but did convey a bias towards expectations for a more profound impact on weight loss w/ longer duration treatment. Reiterate BUY. We believe Phase 2 POMC and LepR data are compelling and have high conviction around positive Phase 3 outcomes in 2019. We believe stock has room for upside around positive Phase 2 trial updates in 1H19, which would expand peak sales potential." (2/26/2018) 4. Cowen Inc analysts commented, "Rhythm released Q3 financials this morning, following the presentation of promising." (11/14/2017) Has Rhythm Pharmaceuticals been receiving favorable news coverage? News coverage about RYTM stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Rhythm Pharmaceuticals earned a coverage optimism score of 1.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. Are investors shorting Rhythm Pharmaceuticals? Rhythm Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totalling 1,263,298 shares, an increase of 39.4% from the October 15th total of 905,923 shares. Based on an average daily volume of 126,301 shares, the short-interest ratio is presently 10.0 days. Currently, 6.8% of the shares of the stock are sold short. View Rhythm Pharmaceuticals' Current Options Chain. Who are some of Rhythm Pharmaceuticals' key competitors? Some companies that are related to Rhythm Pharmaceuticals include Agios Pharmaceuticals (AGIO), Horizon Pharma (HZNP), FibroGen (FGEN), Emergent Biosolutions (EBS), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), Mallinckrodt (MNK), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE) and ACADIA Pharmaceuticals (ACAD). Who are Rhythm Pharmaceuticals' key executives? Rhythm Pharmaceuticals' management team includes the folowing people: Dr. Keith Michael Gottesdiener, Pres, CEO & Director (Age 64)Mr. Hunter C. Smith, CFO & Treasurer (Age 49)Ms. Nithya Desikan, Chief Commercial Officer (Age 39)Mr. Leonardus H.T. van der Ploeg, Chief Scientific Officer (Age 63)Mr. Simon D. Kelner, Chief HR Officer (Age 45) When did Rhythm Pharmaceuticals IPO? (RYTM) raised $100 million in an IPO on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (8.93%), TRV GP LLC (8.73%), FMR LLC (4.76%), BlackRock Inc. (3.34%), Foresite Capital Management IV LLC (2.04%) and JPMorgan Chase & Co. (0.38%). Company insiders that own Rhythm Pharmaceuticals stock include Bros Advisors Lp Baker, David P Meeker, Der Ploeg Leonardus HT Van, James E Flynn, Keith Michael Gottesdiener, Orbimed Advisors Llc and SA Ipsen. View Institutional Ownership Trends for Rhythm Pharmaceuticals. Which major investors are selling Rhythm Pharmaceuticals stock? RYTM stock was sold by a variety of institutional investors in the last quarter, including TRV GP LLC, FMR LLC, Citadel Advisors LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Foresite Capital Management IV LLC and Russell Investments Group Ltd.. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Der Ploeg Leonardus HT Van, Keith Michael Gottesdiener and Orbimed Advisors Llc. View Insider Buying and Selling for Rhythm Pharmaceuticals. Which major investors are buying Rhythm Pharmaceuticals stock? RYTM stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, BlackRock Inc., Greylock Xii GP LLC, Tekla Capital Management LLC, Bank of New York Mellon Corp, Alps Advisors Inc., Credit Suisse AG and Alliancebernstein L.P.. Company insiders that have bought Rhythm Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, David P Meeker, James E Flynn and SA Ipsen. View Insider Buying and Selling for Rhythm Pharmaceuticals. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Rhythm Pharmaceuticals' stock price today? One share of RYTM stock can currently be purchased for approximately $28.44. How big of a company is Rhythm Pharmaceuticals? Rhythm Pharmaceuticals has a market capitalization of $939.82 million. The company earns $-33,700,000.00 in net income (profit) each year or ($2.83) on an earnings per share basis. Rhythm Pharmaceuticals employs 26 workers across the globe. What is Rhythm Pharmaceuticals' official website? The official website for Rhythm Pharmaceuticals is http://www.rhythmtx.com. How can I contact Rhythm Pharmaceuticals? Rhythm Pharmaceuticals' mailing address is 500 BOYLSTON STREET 11TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected] MarketBeat Community Rating for Rhythm Pharmaceuticals (NASDAQ RYTM)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 116 (Vote Outperform)Underperform Votes: 111 (Vote Underperform)Total Votes: 227MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote "Outperform" if you believe RYTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/14/2018 by MarketBeat.com StaffFeatured Article: What is a closed-end mutual fund (CEF)?